Amicus Therapeutics Inc (NASDAQ:FOLD) Institutional Investors Sentiment Index Improved in Q4 2017

April 17, 2018 - By Richard Conner

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Logo

Sentiment for Amicus Therapeutics Inc (NASDAQ:FOLD)

Amicus Therapeutics Inc (NASDAQ:FOLD) institutional sentiment decreased to 1.21 in Q4 2017. Its down -1.12, from 2.33 in 2017Q3. The ratio has dropped, as 88 funds increased and opened new equity positions, while 73 sold and reduced their holdings in Amicus Therapeutics Inc. The funds in our partner’s database now own: 197.59 million shares, up from 192.70 million shares in 2017Q3. Also, the number of funds holding Amicus Therapeutics Inc in their top 10 equity positions increased from 5 to 6 for an increase of 1. Sold All: 25 Reduced: 48 Increased: 63 New Position: 25.

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company has market cap of $2.77 billion. The Company’s principal product is the migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which has completed two global Phase III registration studies. It currently has negative earnings. The firm is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; and AT3375 to treat Parkinson's disease.

The stock increased 2.50% or $0.36 during the last trading session, reaching $14.75. About 1.43M shares traded. Amicus Therapeutics, Inc. (NASDAQ:FOLD) has risen 90.40% since April 17, 2017 and is uptrending. It has outperformed by 78.85% the S&P500.

Analysts await Amicus Therapeutics, Inc. (NASDAQ:FOLD) to report earnings on May, 8. They expect $-0.36 EPS, up 7.69 % or $0.03 from last year’s $-0.39 per share. After $-0.41 actual EPS reported by Amicus Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -12.20 % EPS growth.

Perceptive Advisors Llc holds 8.53% of its portfolio in Amicus Therapeutics, Inc. for 17.89 million shares. Venbio Select Advisor Llc owns 7.26 million shares or 6.77% of their US portfolio. Moreover, Redmile Group Llc has 6.29% invested in the company for 10.03 million shares. The Quebec – Canada-based Sectoral Asset Management Inc has invested 5.13% in the stock. Palo Alto Investors Llc, a California-based fund reported 6.01 million shares.#img1#

Since January 1, 0001, it had 3 insider buys, and 14 sales for $4.83 million activity.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Ratings Coverage

Ratings analysis reveals 100% of Amicus Therapeutics’s analysts are positive. Out of 2 Wall Street analysts rating Amicus Therapeutics, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $20.0 while the high is $24. The stock’s average target of $22 is 49.15% above today’s ($14.75) share price. FOLD was included in 2 notes of analysts from February 8, 2018. The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) earned “Outperform” rating by Leerink Swann on Thursday, February 8. The company was maintained on Wednesday, February 7 by Robert W. Baird.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.